Asia-Pacific Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) - Industry Trends and Forecast to 2029.
Asia-Pacific Anthrax Treatment Market Analysis and Insights
Asia-Pacific anthrax treatment market is driven by the factors such as, rising incidence of bacterial infections, increasing research funding and the development of novel therapies for anthrax treatment and pipeline products enhances its demand as well as rising investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of the anthrax treatment market. The increase in the financial support to the researchers for developing novel interventions, and the rise in the threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and the rise in public-private partnerships for facilitating novel developments for innovative and effective treatment further influence the market. However, the high cost associated with the treatment and procedure as well as stringent government regulations for product approval are expected to hamper the growth for anthrax treatment market.
Asia-Pacific anthrax treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various region and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
Asia-Pacific anthrax treatment market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Asia-Pacific anthrax treatment market will grow at a CAGR of 7.0% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others),End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
Market Players Covered
|
Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Lupin, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., GC Biopharma, corp., among others
|
Asia-Pacific Anthrax Treatment Market Dynamics
Market Definition
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Drivers
- Increasing Prevalence of Anthrax Infections
The incidence of bacterial infections is increasing worldwide. Anthrax is a bacterial infection caused by Bacillus anthracis which is an aerobic, gram-positive spore-forming bacterium. Depending on the route of entry of B. anthracis spores, it occurs primarily as a cutaneous, pulmonary, or gastrointestinal infection. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare. Pulmonary anthrax is the most lethal of the three types of anthrax in which, the spores once inhaled germinate within the tracheobronchial lymph nodes and multiply. Anthrax is a harmful disease that affects both humans and animals. It is a life-threatening infection caused by Bacillus anthracis. Thus, this increasing incidence and prevalence of anthrax infections has developed a need of more diagnostic approaches with increased sensitivity that can detect infection in low volume.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of anthrax treatment market. The increase in the financial support to the researchers for developing novel intervention, and rise in threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and rise in public-private partnerships for facilitating novel developments for the innovative and effective treatment further influence the market.
- Increasing Research Funding and the development of novel therapies for anthrax treatment population
Research and development is a prerequisite in order to modify the procedure intended to treat different kinds of patients. The demand of anthrax treatment is increasing worldwide involving every country. This is why the companies are continuously focusing towards research and development in order to achieve success in providing effective treatment to patients. In these recent years many diagnostic approaches have come forward to take diagnosis to new steps, and many are being made to detect even the lowest volume of parasite in human body.
These new approaches in diagnosis will take the market forward. With the increase in research funding and the development of novel therapies for the treatment of anthrax. There are several novel and pre-existing antibiotics, as well as toxin inhibitors that have shown increasing promise that targets both bacterial growth as well as toxin production for effectively work against anthrax bacterium.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the Asia-Pacific anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the Asia-Pacific market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the Asia-Pacific anthrax treatment market growth.
Recent Development
- In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
- In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.
Asia-Pacific Anthrax Treatment Market Segmentation
Asia-Pacific anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of type, the Asia-Pacific anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.
Route of Administration
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of route of administration, Asia-Pacific anthrax treatment market is segmented into oral, parenteral and others.
End User
- Government Organization
- Hospitals
- Academic and Research Institutes,
- Others
On the basis of end user, Asia-Pacific anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.
Anthrax Treatment Market Regional Analysis/Insights
Asia-Pacific anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.
The countries covered in the anthrax treatment report are Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines and Rest of Asia-Pacific.
The China is expected to dominate due to increasing technological advancement in the developing areas.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Anthrax Treatment Market Share Analysis
Asia-Pacific anthrax treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on anthrax treatment market.
Some players in the market are Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Lupin, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., GC Biopharma, corp., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-